Paolo Paoletti - Genmab AS Independent Director
| GMAB Stock | DKK 1,511 23.00 1.55% |
Insider
Paolo Paoletti is Independent Director of Genmab AS since 2015.
| Age | 68 |
| Tenure | 9 years |
| Phone | (45) 70 20 27 29 |
| Web | www.genmab.com |
Genmab AS Management Efficiency
The company has return on total asset (ROA) of 0.1029 % which means that it generated a profit of $0.1029 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2359 %, meaning that it generated $0.2359 on every $100 dollars invested by stockholders. Genmab AS's management efficiency ratios could be used to measure how well Genmab AS manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Asger Lauritsen | FLSmidth Co | 57 | |
| Jorgen Moeller | DSV Panalpina AS | 70 | |
| Naja Barrise | FLSmidth Co | N/A | |
| Mns Barsne | Ambu AS | N/A | |
| Henrik Ankjr | Ambu AS | N/A | |
| Ehtisham Rabbani | GN Store Nord | N/A | |
| Anders Williamsson | Ambu AS | 69 | |
| Peter Gormsen | GN Store Nord | 49 | |
| Annette Terndrup | FLSmidth Co | 54 | |
| Lars AndersenLange | GN Store Nord | N/A | |
| Russell Thirsk | Bavarian Nordic | N/A | |
| Roland Andersen | FLSmidth Co | 55 | |
| Henrik MSc | Bavarian Nordic | 58 | |
| Steven Block | Ambu AS | 60 | |
| Sofie Lindberg | FLSmidth Co | N/A | |
| Nicolai Thomsen | Ambu AS | N/A | |
| Paul MSc | Bavarian Nordic | 56 | |
| Gunther Pausch | GN Store Nord | N/A | |
| Jannick Denholt | FLSmidth Co | N/A | |
| Thomas Schmidt | Ambu AS | 52 | |
| Anu Kerns | Bavarian Nordic | 51 | |
Management Performance
Genmab AS Leadership Team
Elected by the shareholders, the Genmab AS's board of directors comprises two types of representatives: Genmab AS inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genmab. The board's role is to monitor Genmab AS's management team and ensure that shareholders' interests are well served. Genmab AS's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genmab AS's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Birgitte Stephensen, Senior Vice President IPR & Legal | ||
| Pernille Erenbjerg, Independent Director | ||
| Jonathan Peacock, Independent Director | ||
| Marisol Peron, Corporate Vice President Communications and Investor Relations | ||
| Birgitte MSc, Ex Officer | ||
| Daniel Bruno, Director, Employee Representative | ||
| Peter Kristensen, Director, Employee Representative | ||
| Deirdre Connelly, Independent Deputy Chairman of the Board | ||
| Judith Klimovsky, Executive Vice President Chief Development Officer | ||
| Tahamtan Ahmadi, Executive Vice President, Chief Medical Officer, Head of Experimental Medicines | ||
| Anthony Mancini, Chief Operating Officer, Executive Vice President | ||
| Paolo Paoletti, Independent Director | ||
| Judith MD, Exec Officer | ||
| Anders Pedersen, Non-Independent Director | ||
| Rolf Hoffmann, Independent Director | ||
| Anthony Pagano, Senior Vice President Global Finance and Corporate Development | ||
| Michael Bauer, Senior Vice President Head of Operations R&D | ||
| Martine Vugt, Senior Vice President - Chief of Staff | ||
| Andrew Carlsen, VP Director | ||
| Peter Ros, Sr Accounting | ||
| Jan Winkel, President and Chief Executive Officer | ||
| Mijke Zachariasse, Director, Employee Representative | ||
| Rima Nassar, Director, Employee Representative |
Genmab Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Genmab AS a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.24 | |||
| Return On Asset | 0.1 | |||
| Profit Margin | 0.47 % | |||
| Operating Margin | 0.38 % | |||
| Current Valuation | 186.33 B | |||
| Shares Outstanding | 65.96 M | |||
| Shares Owned By Institutions | 49.90 % | |||
| Price To Earning | 34.78 X | |||
| Price To Book | 7.86 X | |||
| Price To Sales | 17.00 X |
Pair Trading with Genmab AS
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Genmab AS position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Genmab AS will appreciate offsetting losses from the drop in the long position's value.Moving together with Genmab Stock
| 0.93 | NOVO-B | Novo Nordisk AS | PairCorr |
| 0.8 | ALK-B | ALK Abell AS | PairCorr |
| 0.87 | BAVA | Bavarian Nordic | PairCorr |
| 0.74 | ZEAL | Zealand Pharma AS | PairCorr |
Moving against Genmab Stock
| 0.86 | DSV | DSV Panalpina AS | PairCorr |
| 0.85 | FLS | FLSmidth | PairCorr |
| 0.47 | ISS | ISS AS | PairCorr |
| 0.43 | ORPHA | Orphazyme AS | PairCorr |
The ability to find closely correlated positions to Genmab AS could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Genmab AS when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Genmab AS - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Genmab AS to buy it.
The correlation of Genmab AS is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Genmab AS moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Genmab AS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Genmab AS can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Information and Resources on Investing in Genmab Stock
When determining whether Genmab AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab AS's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Genmab Stock, please use our How to Invest in Genmab AS guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.